Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v12-FR | Version v11-FR | |
---|---|---|
Language | French | French |
Date Updated | 2023-02-01 | 2023-02-01 |
Drug Identification Number | 02377209 | 02377209 |
Brand name | NOVORAPID | NOVORAPID |
Common or Proper name | NOVORAPID FLEXTOUCH 100U 5X3ML | NOVORAPID FLEXTOUCH 100U 5X3ML |
Company Name | NOVO NORDISK CANADA INC | NOVO NORDISK CANADA INC |
Ingredients | INSULIN ASPART | INSULIN ASPART |
Strength(s) | 100UNIT | 100UNIT |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | SUBCUTANEOUS SUBCUTANEOUS | SUBCUTANEOUS SUBCUTANEOUS |
Packaging size | EA | EA |
ATC code | A10AB | A10AB |
ATC description | INSULINS AND ANALOGUES | INSULINS AND ANALOGUES |
Reason for discontinuation | Business reasons | Business reasons |
Anticipated discontinuation date | 2023-07-31 | 2023-07-31 |
Actual discontinuation date | ||
Remaining supply date | 2023-07-01 | 2023-07-01 |
Discontinuation status | To be discontinued | To be discontinued |
Discontinuation decision reversal | no | no |
Tier 3 Status | No | No |
Information on remaining supply | ||
Company comments | Patients who continue to have coverage for NovoRapid® FlexTouch® have the option to transition to the Penfill® format with NovoPen® 4, our durable insulin device that is available free-of-charge for patients at the pharmacy. | Patients who continue to have coverage for NovoRapid® FlexTouch® have the option to transition to the Penfill® format with NovoPen® 4, our durable insulin device that is available free-of-charge for patients at the pharmacy. |
Health Canada comments |